Syncona's Purespring raises £80m in new financing
Syncona Limited NPV
99.80p
16:40 20/12/24
0.20%
0.20p
Life science investor Syncona said its portfolio company Purespring Therapeutics, which focuses on gene therapies for kidney diseases, had raised £80m in an oversubscribed financing.
Equity Investment Instruments
12,067.95
17:14 20/12/24
0.48%
58.07
FTSE 250
20,450.69
17:14 20/12/24
n/a
n/a
FTSE 350
4,463.29
17:14 20/12/24
n/a
n/a
FTSE All-Share
4,421.11
17:04 20/12/24
n/a
n/a
Syncona has committed £19.9m as part of a syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient Capital, the company said on Wednesday.
The latest financing brings Purespring’s total fundraising to date to around £115m. Proceeds will be used to advance its therapies pipeline and support the expected initiation of a phase I/II clinical trial in 2026 for its lead programme targeting IgA Nephropathy (IgAN), a chronic kidney disease principally affecting young adults.
Reporting by Frank Prenesti for Sharecast.com